# Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

> **NCT01396187** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 50 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** PF-05231023
- **DRUG:** PF-05231023
- **DRUG:** PF-05231023
- **DRUG:** PF-05231023
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01396187
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2015-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01396187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01396187, "Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01396187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*